Literature DB >> 28185838

Vitamin K status in cystic fibrosis patients with liver cirrhosis.

Patrycja Krzyżanowska1, Sławomira Drzymała-Czyż1, Andrzej Pogorzelski2, Monika Duś-Żuchowska1, Wojciech Skorupa3, Lyudmyla Bober4, Ewa Sapiejka5, Beata Oralewska6, Nataliya Rohovyk4, Jerzy Moczko7, Jan Nowak1, Ewa Wenska-Chyży1, Marta Rachel8, Aleksandra Lisowska1, Jarosław Walkowiak9.   

Abstract

The available data on the influence of liver cirrhosis on vitamin K status in CF patients is scarce. Therefore, the aims of the present study were to assess the prevalence of vitamin K deficiency in cirrhotic CF subjects and to determine whether it correlates with liver cirrhosis. The study group comprised of 27 CF patients with and 63 without liver cirrhosis. Vitamin K status was assessed using prothrombin induced by vitamin K absence (PIVKA-II) and the percentage of undercarboxylated osteocalcin (u-OC). PIVKA-II concentrations were higher in cirrhotic than in non-cirrhotic CF patients (median [1st-3rd quartile]: 3.2ng/ml [1.0-10.0] vs. 1.3ng/ml [0.2-2.6], p=0.0029). However, the differences in u-OC percentages between the studied groups did not reach the level of significance (49.4% [7.0-73.8] vs. 8.0% [2.6-59.1], p=0.0501). Based on multiple linear regression analysis the dose of vitamin K and F508del mutation were potentially defined as determinants of vitamin K deficiency. Liver cirrhosis was not documented to be an independent risk factor. In CF patients with liver cirrhosis vitamin K deficiency is not only more frequent, but also more severe. However, not liver cirrhosis, but the presence of a F508del CFTR mutation constitutes an independent risk factor for vitamin K deficiency.
Copyright © 2017 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Fat-soluble vitamin; Hepatology diseases; Prothrombin inducted by vitamin K absence-II; Undercarboxylated osteocalcin

Mesh:

Substances:

Year:  2017        PMID: 28185838     DOI: 10.1016/j.dld.2017.01.155

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  4 in total

1.  Clinical effect of single covered stent and double covered stent on TIPS in the treatment of hemorrhage due to rupture of esophageal and gastric varices in cirrhosis and its influence on immune function.

Authors:  Bo Xu; Jia Liu; Shunhai Liu; Xin Xiang; Liang Lai
Journal:  Exp Ther Med       Date:  2019-10-15       Impact factor: 2.447

2.  Fat-Soluble Vitamin Supplementation Using Liposomes, Cyclodextrins, or Medium-Chain Triglycerides in Cystic Fibrosis: A Randomized Controlled Trial.

Authors:  Jan K Nowak; Paulina Sobkowiak; Sławomira Drzymała-Czyż; Patrycja Krzyżanowska-Jankowska; Ewa Sapiejka; Wojciech Skorupa; Andrzej Pogorzelski; Agata Nowicka; Irena Wojsyk-Banaszak; Szymon Kurek; Barbara Zielińska-Psuja; Aleksandra Lisowska; Jarosław Walkowiak
Journal:  Nutrients       Date:  2021-12-20       Impact factor: 5.717

3.  Cystic fibrosis related liver disease and endocrine considerations.

Authors:  Jordan S Sherwood; Jagdeesh Ullal; Katherine Kutney; Kara S Hughan
Journal:  J Clin Transl Endocrinol       Date:  2021-12-13

4.  Fat-Soluble Vitamins in Standard vs. Liposomal Form Enriched with Vitamin K2 in Cystic Fibrosis: A Randomized Multi-Center Trial.

Authors:  Jan Krzysztof Nowak; Patrycja Krzyżanowska-Jankowska; Sławomira Drzymała-Czyż; Joanna Goździk-Spychalska; Irena Wojsyk-Banaszak; Wojciech Skorupa; Ewa Sapiejka; Anna Miśkiewicz-Chotnicka; Jan Brylak; Barbara Zielińska-Psuja; Aleksandra Lisowska; Jarosław Walkowiak
Journal:  J Clin Med       Date:  2022-01-17       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.